Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nima Aghili

Interventional Cardiology Lakewood, CO Medical Doctor

NPI 1043487655 CMS profile 183981

11700 W 2Nd Pl, Suite 350, Lakewood, CO 80228

Open in the dashboard

General payments

$220,057

891 records reported · program years 2019–2025

Research payments

$350

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,000 paid to institutions, not to them · program year 2020

Through program year 2025, Nima Aghili of Lakewood, CO is reported in the CMS Open Payments database as having received $220,057 across 891 general payments and $350 in research payments paid to them. Separately, studies naming them as principal investigator received $1,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $34,480 129
2024 General $45,786 163
2023 General $38,921 158
2023 Research $201 2
2022 General $40,600 136
2022 Research $149 1
2021 General $36,012 128
2020 General $1,272 46
2019 General $22,985 131

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nima Aghili
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Nima Aghili were reported at $34,480. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Nima Aghili Interventional Cardiology median Middle half National median
2019 $22,985 $1,097 $329–$3,048 $163
2020 $1,272 $473 $161–$1,480 $114
2021 $36,012 $677 $233–$1,827 $132
2022 $40,600 $978 $333–$2,724 $149
2023 $38,921 $1,136 $382–$2,986 $160
2024 $45,786 $1,181 $395–$3,326 $164
2025 $34,480 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abiomed $112,735 193 payments
  2. Janssen Pharmaceuticals, Inc $56,096 52 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $16,805 27 payments
  4. Medtronic, Inc. $13,243 90 payments
  5. Abbott Laboratories $3,661 51 payments
  6. Boston Scientific Corporation $2,768 133 payments
  7. Edwards Lifesciences Corporation $2,565 33 payments
  8. Lilly USA, LLC $2,500 2 payments
  9. AngioDynamics, Inc. $2,409 6 payments
  10. W. L. Gore & Associates, Inc. $986 33 payments
  11. Other $6,290 271 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $83,380 33 payments
  2. Honoraria $70,600 21 payments
  3. Travel and Lodging $30,591 70 payments
  4. Food and Beverage $24,364 755 payments
  5. Consulting Fee $10,815 6 payments
  6. Debt forgiveness $224 2 payments
  7. Education $82 4 payments
Products named General payments · program years 2019–2025
  1. Impella $91,074 148 payments
  2. XARELTO $56,096 52 payments
  3. JARDIANCE Diabetes $16,630 17 payments
  4. COREVALVE EVOLUT R $11,500 50 payments
  5. Mitra Clip system $2,772 16 payments
  6. JARDIANCE Diabetes $2,500 2 payments
  7. PASCAL $1,497 11 payments
  8. WATCHMAN Access System $1,391 67 payments
  9. Repatha $553 30 payments
  10. VERQUVO $546 32 payments
  11. Other $11,521 436 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Abiomed $350 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

4,154

Median for Cardiology: 2,533

Drug cost

$1,038,779

Median for Cardiology: $485,213

Branded share of claims

32%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 284 $332,200
Entresto Sacubitril/Valsartan Brand 162 $213,568
Xarelto Rivaroxaban Brand 180 $211,107
Repatha Sureclick Evolocumab Brand 173 $132,090
Jardiance Empagliflozin Brand 68 $85,245
Farxiga Dapagliflozin Propanediol Brand 23 $14,411
Prasugrel Hcl Generic 53 $5,525
Metoprolol Succinate Generic 312 $3,677
Torsemide Generic 120 $3,589
Rosuvastatin Calcium Generic 254 $3,397

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$209,660

Of which drugs: $1,036

Medicare patients

813

Average age 75

Services billed

2,836

376 women, 437 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 49%
Heart failure 34%
Atrial fibrillation 34%
Chronic kidney disease 29%
Diabetes 28%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 39 154 $1,036

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $7,972
  • Lilly USA, LLC $781
$8,753 68 —
VERQUVO
  • Merck Sharp & Dohme Corporation $150
$150 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $86
  • PFIZER INC. $11
$96 284 —
LEQVIO
  • Novartis Pharmaceuticals Corporation $85
$85 — —
VYNDAQEL
  • PFIZER INC. $67
$67 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

894 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record